Product Code: PHA1158
The global mRNA Vaccines & Therapeutics market was valued at US$58,452.6 million in 2021 and is projected to change at a CAGR of -7.89% during the forecast period 2022-2032.
“The mRNA Vaccines & Therapeutics Market Report 2022-2032”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
CDMOs Seizing Opportunities in the Newly Commercializing mRNA Market
A successful application of mRNA technology for COVID-19 has reinvigorated biopharmaceutical companies to further explore opportunities of this technology for other diseases. There has been a significant increase in therapeutic mRNA programs that are focused on mRNA and its delivery platform, which is the major challenge for the delivery of mRNA into the cells. The Contract Development and Manufacturing Organisations (CDMOs) have also been compelled to ramp in their production capabilities to meet this surge in demand. Many existing CDMOs have made huge capital investments through developing and upgrading their manufacturing capabilities and processes to match GMP standards for vaccine development. These companies are making strategic partnerships and acquisitions to fortify their mRNA manufacturing technologies. For instance, Korea-based Samsung Biologics had signed an agreement with Moderna in May 2021 for aseptic fill-finish and packaging and labeling of Moderna's COVID-19 mRNA vaccine. In August 2021 Samsung Biologics announced its plan in three areas which included capacity expansion setting up an R&D center in the U.S. for support of its clients at a global scale, and expansion of the platform to support diverse applications.
What Questions Should You Ask before Buying a Market Research Report?
- How is the mRNA vaccines & therapeutics market evolving?
- What is driving and restraining the mRNA vaccines & therapeutics market?
- How will each mRNA vaccines & therapeutics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
- How will the market shares for each mRNA vaccines & therapeutics submarket develop from 2022 to 2032?
- What will be the main driver for the overall market from 2022 to 2032?
- Will leading mRNA vaccines & therapeutics markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
- Who are the leading players and what are their prospects over the forecast period?
- What are the mRNA vaccines & therapeutics projects for these leading companies?
- How will the industry evolve during the period between 2022 and 2032? What are the implications of mRNA vaccines & therapeutics projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the mRNA Vaccines & Therapeutics market?
- Where is the mRNA vaccines & therapeutics market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the mRNA Vaccines & Therapeutics market today, and over the next 10 years:
- Our 411-page report provides 164 tables and 242 charts/graphs exclusively to you.
- The report highlights key lucrative areas in the industry so you can target them - NOW.
- It contains in-depth analysis of global, regional and national sales and growth.
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the mRNA Vaccines & Therapeutics Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2032 and other analyses reveal commercial prospects
- In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
- You will find original analyses, with business outlooks and developments.
- Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising mRNA Vaccines & Therapeutics recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.
Segments Covered in the Report
mRNA Vaccines & Therapeutics Market by Types
- mRNA Prophylactic Vaccines
- Therapeutics Vaccines
- mRNA Therapeutics
mRNA Vaccines & Therapeutics Market by Vectors
- Self-amplifying mRNA
- Non-amplifying mRNA
mRNA Vaccines & Therapeutics Market by Vector Delivery Platforms
- Naked mRNA
- Cell Specific
- Carrier Mediated
- Viral
- Non-Viral (Polymer-based Vectors, Lipid Nanoparticles, Peptide-based Vectors)
mRNA Vaccines & Therapeutics Market by Route of Administration
- Intramuscular
- Intravenous
- Intradermal
- Subcutaneous
- Intranodal
mRNA Vaccines & Therapeutics Market by Application
- Cell Therapy
- Protein Replacement Therapy
- Gene Editing
- Cancer Immunotherapy
- Infectious Diseases (including COVID-19)
mRNA Vaccines & Therapeutics Market by End-Users
- Hospitals & Clinics
- Research Organizations
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for four regional and 20 leading national markets:
North America
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
MEA
- Saudi Arabia
- UAE
- Turkey
- Rest of MEA
The report also includes profiles and for some of the leading companies in the mRNA Vaccines & Therapeutics Market Report 2022-2032, with a focus on this segment of these companies' operations.
Leading companies and the potential for market growth
- AstraZeneca PLC
- Moderna
- CureVac N.V.
- BioNTech SE
- Pfizer Inc.,
- GSK PLC
- Arcturus Therapeutics Holding Inc.
- Translate Bio (now a Sanofi Company)
- Sanofi
- eTheRNA
- Stemirna Therapeutics
- Cartesian Therapeutics
- Ethris
Overall world revenue for mRNA Vaccines & Therapeutics Market, 2022 to 2032 in terms of value the market will surpass US$64,338 million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the mRNA Vaccines & Therapeutics Market, 2022 to 2032 report help you?
In summary, our 410+ page report provides you with the following knowledge:
- Revenue forecasts to 2032 for mRNA Vaccines & Therapeutics Market, 2022 to 2032 Market, with forecasts for services, company size, drug type, and therapeutic area each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2032 for four regional and 22 key national markets - See forecasts for the mRNA Vaccines & Therapeutics Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
- Prospects for established firms and those seeking to enter the market - including company profiles for 13 of the major companies involved in the mRNA Vaccines & Therapeutics Market, 2022 to 2032.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the mRNA Vaccines & Therapeutics Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.
Table of Contents
1. Report Overview
- 1.1 Objectives of the Study
- 1.2 Introduction to mRNA Vaccines & Therapeutics Market
- 1.3 What This Report Delivers
- 1.4 Why You Should Read This Report
- 1.5 Key Questions Answered By This Analytical Report Include:
- 1.6 Who is This Report For?
- 1.7 Methodology
- 1.7.1 Market Definitions
- 1.7.2 Market Evaluation & Forecasting Methodology
- 1.7.3 Data Validation
- 1.7.3.1 Primary Research
- 1.7.3.2 Secondary Research
- 1.8 Frequently Asked Questions (FAQs)
- 1.9 Associated Reports
- 1.10 About
2 Executive Summary
3 Market Overview
- 3.1 Key Findings
- 3.2 Market Dynamics
- 3.2.1 Market Driving Factors
- 3.2.1.1 Growing Diverse Applications of mRNA Post COVID-19 Vaccine Success
- 3.2.1.2 Significant Research Funding to Boost Market Growth
- 3.2.1.3 Technological Advances Driving the Market Growth
- 3.2.2 Market Restraining Factors
- 3.2.2.1 Scalability and Cost-Effectiveness is Still a Major Bottleneck
- 3.2.3 Market Opportunities
- 3.2.3.1 mRNA Cancer Vaccines
- 3.2.3.2 Analytics, Machine Learning and Cloud Data Warehousing
- 3.3 COVID-19 Impact Analysis
- 3.4 Porter's Five Forces Analysis
- 3.4.1 Bargaining Power of Suppliers
- 3.4.2 Bargaining Power of Buyers
- 3.4.3 Competitive Rivalry
- 3.4.4 Threat of Substitutes
- 3.4.5 Threat of New Entrants
- 3.5 PEST Analysis
- 3.5.1 Political Factors
- 3.5.2 Economic Factors
- 3.5.3 Social Factors
- 3.5.4 Technological Factors
4 Global mRNA vaccines & therapeutics Market, By Type
- 4.1 Key Findings
- 4.2 Type Segment Growth Prospects
- 4.3 Global mRNA vaccines & therapeutics Market Size Estimation and Forecast by Type
- 4.4 Prophylactic vaccines
- 4.4.1 Market Size by Region, 2022-2032 (US$ Mn)
- 4.4.2 Market Share by Region, 2022-2032 (%)
- 4.5 Therapeutic Vaccines Market
- 4.5.1 Therapeutics Vaccines Market Forecast by Region, 2022-2032 (US$ Mn)
- 4.5.2 Therapeutic Vaccine Forecast by Region, 2022-2032 (%)
- 4.6 mRNA Therapeutics Market Forecast
- 4.6.1 mRNA Therapeutics Market Forecast by Region 2022-2032 (US$ Mn)
- 4.6.2 mRNA Therapeutics Market by Region, 2022-2032 (%)
5 mRNA Vaccines & Therapeutics Market Analysis by Applications
- 5.1 Key Findings
- 5.2 Applications Segment Growth Prospects
- 5.3 Global mRNA vaccines & therapeutics Market Size Estimation and Forecast by Applications
- 5.4 mRNA vaccines & therapeutics Market Share by Applications, 2022 & 2032
- 5.5 Cell Therapy
- 5.5.1 Cell Therapy Market Forecast by Region, 2022-2032 (US$ Mn)
- 5.5.2 Cell Therapy Market Share by Region, 2022-2032 (%)
- 5.6 Gene Editing
- 5.6.1 Gene Editing Market Forecast by Region, 2022-2032 (US$ Mn)
- 5.6.2 Gene Editing Market Share by Region, 2022-2032 (%)
- 5.7 Protein Replacement Therapy
- 5.7.1 Protein Replacement Market Forecast by Region, 2022-2032 (US$ Mn)
- 5.7.2 Protein Replacement Market Share by Region, 2022-2032 (%)
- 5.8 Cancer Immunotherapy
- 5.8.1 Cancer Immunotherapy Market Forecast by Region, 2022-2032 (US$ Mn)
- 5.8.2 Cancer Immunotherapy Market Share by Region, 2022-2032 (%)
- 5.9 Infectious Diseases
- 5.9.1 Infectious Diseases Market Forecast by Region, 2022-2032 (US$ Mn)
- 5.9.2 mRNA Infectious Diseases Application Market Share by Region, 2022-2032 (%)
6 mRNA Vaccine & Therapeutics Market, By Vector Platform
- 6.1 Key Findings
- 6.2 Vector Platform Segment Growth Prospects
- 6.3 Global mRNA vaccines & therapeutics Market Size Estimation and Forecast by Vector Platform
- 6.4 Global mRNA vaccines & therapeutics Market Share by Vector Platforms, 2022 & 2032
- 6.5 Self-Amplifying mRNA
- 6.5.1 Self-Amplifying mRNA Market Forecast by Region, 2022-2032 (US$ Mn)
- 6.5.2 Self-Amplifying mRNA Market Share by Region, 2022-2032 (%)
- 6.6 Non-Amplifying (Conventional) mRNA
- 6.6.1 Non-Amplifying mRNA Market Forecast by Region, 2022-2032 (US$ Mn)
- 6.6.2 Non-Amplifying mRNA Market Share by Region, 2022-2032 (%)
7 Global mRNA Vaccines & Therapeutics Market, By Delivery Mode
- 7.1 Key Findings
- 7.2 Delivery Platform Segment Growth Prospects
- 7.3 Global mRNA Vaccines & Therapeutics Market Size Estimation and Forecast, by Delivery Platform, 2022 & 2032
- 7.4 Naked mRNA Delivery
- 7.4.1 Naked Delivery Platform Forecast by Region, 2022-2032 (US$ Mn)
- 7.4.2 Naked Delivery Platform Market Share by Region, 2022-2032 (%)
- 7.5 Cell-Specific Delivery Platform
- 7.5.1 Cell Specific Delivery Platform by Region, 2022-2032 (US$ Mn)
- 7.5.2 Cell Specific Delivery Platform Market Share by Region, 2022-2032 (%)
- 7.6 Carrier Mediated
- 7.6.1 Carrier Mediated Delivery Platform Market by Region, 2022-2032 (US$ Mn)
- 7.6.2 Carrier Mediated Platform Market Share by Region, 2022-2032 (%)
- 7.6.3 Carrier Mediated Delivery Platform Market by Types, 2022-2032 (US$ Mn)
7.6.3.1.1.1 Viral Vector Market by Region, 2022-2032 (US$ Mn)
7.6.3.1.1.2 Viral Vector Market Share by Region, 2022-2032 (%)
7.6.3.2.1 Non-Viral Market by Region, 2022-2032 (US$ Mn)
7.6.3.2.2 Non-Viral Market Share by Region, 2022-2032 (%)
- 7.6.3.3 Non-Viral Vector Market by Types, 2022-2032 (US$ Mn)
7.6.3.3.1.1 Lipid Nanoparticles (LNP)
7.6.3.3.1.2 Peptide-based Vectors
7.6.3.3.1.3 Polymer-based Vectors
8 Global mRNA Vaccines & Therapeutics Market, By Route of Delivery
- 8.1 Key Findings
- 8.2 Route of Delivery Segment Growth Prospects
- 8.3 Global mRNA vaccines & therapeutics Market Size Estimation and Forecast, by Route of Delivery, 2022 & 2032
- 8.4 Intradermal
- 8.4.1 Intradermal Route of Delivery Forecast by Region, 2022-2032 (US$ Mn)
- 8.4.2 Intradermal Route of Delivery Forecast by Region, 2022-2032 (%)
- 8.5 Subcutaneous
- 8.5.1 Subcutaneous Route of Delivery Forecast by Region, 2022-2032 (US$ Mn)
- 8.5.2 Subcutaneous Route of Delivery Forecast by Region, 2022-2032 (%)
- 8.6 Intramuscular
- 8.6.1 Intramuscular Route of Delivery Forecast by Region, 2022-2032 (US$ Mn)
- 8.6.2 Intramuscular Route of Delivery Forecast by Region, 2022-2032 (%)
- 8.7 Intravenous
- 8.7.1 Intravenous Route of Delivery Forecast by Region, 2022-2032 (US$ Mn)
- 8.7.2 Intravenous Route of Delivery Forecast by Region, 2022-2032 (%)
- 8.8 Intranodal
- 8.8.1 Intranodal Route of Delivery Forecast by Region, 2022-2032 (US$ Mn)
- 8.8.2 mRNA Intranodal Route of Delivery Forecast by Region, 2022-2032 (%)
9 Global mRNA Based Therapeutics and Vaccine Market by End-User
- 9.1 Key Findings
- 9.2 End Users Segment Growth Prospects
- 9.3 Global mRNA vaccines & therapeutics Market Size Estimation, by End Users, 2022 & 2032
- 9.4 Research Organizations
- 9.4.1 Research Organizations Market Forecast, By End Users, by Region, 2022-2032 (US$ Mn)
- 9.4.2 Research Organizations Market Share by Region, 2022-2032 (%)
- 9.5 Hospitals & Clinics Segment Market Forecast, 2022-2032
- 9.5.1 Hospitals & Clinics Market Forecast by Region, 2022-2032 (US$ Mn)
- 9.5.2 Hospitals & Clinics Market Forecast, by Region, 2022-2032 (%)`
10 Global mRNA vaccines & therapeutics Market Analysis by Region
- 10.1 Key Findings
- 10.2 Regional Market Size Estimation and Forecast
- 10.3 COVID-19 Impact Analysis: Recovery Scenarios (V, U, W, L)
11 North America mRNA Vaccines & Therapeutics Market Analysis
- 11.1 Key Findings
- 11.2 North America mRNA Vaccines & Therapeutics Market Attractiveness Index
- 11.3 North America mRNA Vaccines & Therapeutics Market by Country, 2022, 2027 & 2032 (US$ mn)
- 11.4 North America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Country
- 11.5 North America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Types
- 11.6 North America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Vector Platform
- 11.7 North America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Vector Delivery Platform
- 11.7.1 North America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Carrier Mediated Vector Delivery Platform
- 11.7.1.1 North America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Non-Viral Vector Delivery Platform
- 11.8 North America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Applications
- 11.9 North America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Route of Delivery
- 11.10 North America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast, by End-Users
- 11.11 North America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast, by Country
- 11.11.1 U.S.
- 11.11.2 Canada
12 Europe mRNA Vaccines & Therapeutics Market Analysis
- 12.1 Key Findings
- 12.2 Europe mRNA Vaccines & Therapeutics Market Attractiveness Index
- 12.3 Europe mRNA Vaccines & Therapeutics Market by Country, 2022, 2027 & 2032 (US$ mn)
- 12.4 Europe mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Country
- 12.5 Europe mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Types
- 12.6 Europe mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Vector Platform
- 12.7 Europe mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Vector Delivery Platform
- 12.7.1 Europe mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Carrier Vector Delivery Platform
- 12.7.1.1 Europe mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Non-Viral Vector Delivery Platform
- 12.8 Europe mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Applications
- 12.9 Europe mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Route of Delivery
- 12.10 Europe mRNA Vaccines & Therapeutics Market Size Estimation and Forecast, by End-Users
- 12.11 Europe mRNA Vaccines & Therapeutics Market Size Estimation and Forecast, by Country
- 12.11.1 Germany
- 12.11.2 U.K.
- 12.11.3 France
- 12.11.4 Spain
- 12.11.5 Italy
- 12.11.6 Rest of Europe
13 Asia Pacific mRNA Vaccines & Therapeutics Market Analysis
- 13.1 Key Findings
- 13.2 Asia Pacific mRNA Vaccines & Therapeutics Market Attractiveness Index
- 13.3 Asia Pacific mRNA Vaccines & Therapeutics Market by Country, 2022, 2027 & 2032 (US$ Mn)
- 13.4 Asia Pacific mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Country
- 13.5 Asia Pacific mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Types
- 13.6 Asia Pacific mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Vector Platform
- 13.7 Asia Pacific mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Vector Delivery Platform
- 13.7.1 Asia Pacific mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Carrier Mediated Vector Delivery Platform
- 13.7.1.1 Asia Pacific mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Carrier Mediated Non-Viral Vector Delivery Platform
- 13.8 Asia Pacific mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Applications
- 13.9 Asia Pacific mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Route of Delivery
- 13.10 Asia Pacific mRNA Vaccines & Therapeutics Market Size Estimation and Forecast, by End-Users
- 13.11 Asia Pacific mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Country
- 13.11.1 China
- 13.11.2 India
- 13.11.3 Japan
- 13.11.4 South Korea
- 13.11.5 Australia
- 13.11.6 Rest of Asia Pacific
14 Latin America mRNA Vaccines & Therapeutics Market Analysis
- 14.1 Key Findings
- 14.2 Latin America mRNA Vaccines & Therapeutics Market Attractiveness Index
- 14.3 Latin America mRNA Vaccines & Therapeutics Market by Country, 2022, 2027 & 2032 (US$ Mn)
- 14.4 Latin America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Country
- 14.5 Latin America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Types
- 14.6 Latin America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Vector Platform
- 14.7 Latin America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Vector Delivery Platform
- 14.7.1 Latin America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Carrier Mediated Vector Delivery Platform
- 14.7.1.1 Latin America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Carrier Mediated Non-Viral Vector Delivery Platform
- 14.8 Latin America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Applications
- 14.9 Latin America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Route of Delivery
- 14.10 Latin America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast, by End-Users
- 14.10.1 Brazil
- 14.10.2 Argentina
- 14.10.3 Mexico
- 14.10.4 Rest of Latin America
15 Middle East & Africa mRNA Vaccine & Therapeutics Market Analysis
- 15.1 Key Findings
- 15.2 Middle East & Africa mRNA Vaccines & Therapeutics Market Attractiveness Index
- 15.3 Middle East & Africa mRNA Vaccines & Therapeutics Market by Country, 2022, 2027 & 2032 (US$ Mn)
- 15.4 Middle East & Africa mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Country
- 15.5 Middle East & Africa mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Types
- 15.6 Middle East & Africa mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Vector Platform
- 15.7 Middle East & Africa mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Vector Delivery Platform
- 15.7.1 Middle East & Africa mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Carrier Mediated Vector Delivery Platform
- 15.7.1.1 Middle East & Africa mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Carrier Mediated Non-Viral Vector Delivery Platform
- 15.8 Middle East & Africa mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Applications
- 15.9 Middle East & Africa mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Route of Delivery
- 15.10 Middle East & Africa mRNA vaccines & therapeutics Market Size Estimation and Forecast, by End-Users
- 15.10.1 Saudi Arabia
- 15.10.2 UAE
- 15.10.3 Turkey
- 15.10.4 South Africa
- 15.10.5 Rest of Middle East & Africa
16 Company Profiles
- 16.1 Company Share Analysis
- 16.2 Key Business Strategy Analysis
- 16.3 AstraZeneca PLC
- 16.3.1 Company Snapshot
- 16.3.2 Company Overview
- 16.3.3 Financial Analysis
- 16.3.3.1 Net Revenue, 2017-2021
- 16.3.3.2 Core Operating Profit, 2017-2021
- 16.3.3.3 R&D, 2017-2021
- 16.3.3.4 Regional Pharmaceutical Market Revenue, 2017-2021
- 16.3.4 AstraZeneca: COVID Vaccine Sales, 2021
- 16.3.5 AstraZeneca PLC: Development Pipeline
- 16.3.6 Strategic Outlook
- 16.4 Moderna
- 16.4.1 Company Snapshot
- 16.4.2 Company Overview
- 16.4.3 Financial Analysis
- 16.4.3.1 Net Revenue, 2017-2021
- 16.4.3.2 R&D Expense, 2017-2021
- 16.4.3.3 Regional Pharmaceutical Market Shares, 2021
- 16.4.4 Moderna: Vaccines & Therapeutics Development Pipeline
- 16.4.5 Strategic Outlook
- 16.5 CureVac N.V.
- 16.5.1 Company Snapshot
- 16.5.2 Company Overview
- 16.5.3 Financial Analysis
- 16.5.3.1 Net Revenue, 2018-2021
- 16.5.3.2 CureVac N.V. Revenues from Contract Customers: 2018-2021
- 16.5.3.3 R&D Expense, 2018-2021
- 16.5.3.4 Regional Pharmaceutical Market Shares (%), 2018-2021
- 16.5.4 CureVac N.V.: Vaccines & Therapeutics Development Pipeline
- 16.5.5 Strategic Outlook
- 16.6 BioNTech SE
- 16.6.1 Company Snapshot
- 16.6.2 Company Overview
- 16.6.3 Financial Analysis
- 16.6.3.1 Net Revenue, 2018-2021
- 16.6.3.2 BioNTech SE Revenues from R&D Collaborations: 2018-2021
- 16.6.3.3 R&D Expense, 2018-2021
- 16.6.3.4 Regional Revenues by Collaborations (US$ Million), 2018-2021
- 16.6.4 BioNTech SE: Vaccines & Therapeutics Development Pipeline
- 16.6.5 Strategic Outlook
- 16.7 Pfizer Inc.
- 16.7.1 Company Snapshot
- 16.7.2 Company Overview
- 16.7.3 Financial Analysis
- 16.7.3.1 Net Revenue, 2017-2021
- 16.7.3.2 Net Income: 2017-2021
- 16.7.4 Pfizer Inc.: mRNA Vaccine Approval Status
- 16.7.5 Strategic Outlook
- 16.8 GSK Plc.
- 16.8.1 Company Snapshot
- 16.8.2 Company Overview
- 16.8.3 Financial Analysis
- 16.8.3.1 Net Revenue, 2017-2021
- 16.8.3.2 R&D Expense: 2017-2021
- 16.8.3.3 Geographic Revenues, By Segment, 2019-2021
- 16.8.3.4 Regional Revenues (US$ Million), 2018-2021
- 16.8.4 GSK Inc.: mRNA Vaccine Pipeline Status
- 16.8.5 Strategic Outlook
- 16.9 Arcturus Therapeutics Holdings Inc.
- 16.9.1 Company Snapshot
- 16.9.2 Company Overview
- 16.9.3 Financial Analysis
- 16.9.3.1 Net Revenue, 2019-2021
- 16.9.3.2 Arcturus Therapeutics Holdings Inc., Collaboration Revenues (2019-2021)
- 16.9.4 Arcturus Therapeutics Holdings Inc: mRNA Vaccine Pipeline Status
- 16.9.5 Strategic Outlook
- 16.10 Translate Bio ( now A Sanofi Company)
- 16.10.1 Company Snapshot
- 16.10.2 Company Overview
- 16.10.3 Financial Analysis
- 16.10.3.1 Net Revenue, 2018-2020
- 16.10.3.2 R&D Expense (US$ Million), 2018-2020
- 16.10.4 Translate Bio (a Sanofi Company): mRNA Vaccine Pipeline Status
- 16.10.5 Strategic Outlook
- 16.11 Sanofi
- 16.11.1 Company Snapshot
- 16.11.2 Company Overview
- 16.11.3 Financial Analysis
- 16.11.3.1 Net Revenue, 2017-2021
- 16.11.3.2 R&D Expense (US$ Million), 2017-2021
- 16.11.3.3 Sanofi, Net Income (2017-2021)
- 16.11.4 Sanofi Company: mRNA Vaccine Pipeline Status
- 16.11.5 Strategic Outlook
- 16.12 eTheRNA
- 16.12.1 Company Snapshot
- 16.12.2 Company Overview
- 16.12.3 Partnerships/ Strategic Collaborations
- 16.12.4 Strategic Outlook
- 16.13 Stemirna Therapeutics
- 16.13.1 Company Snapshot
- 16.13.2 Company Overview
- 16.13.3 Stemirna: mRNA Vaccine Pipeline Status
- 16.14 Cartesian Therapeutics
- 16.14.1 Company Snapshot
- 16.14.2 Company Overview
- 16.14.3 Cartesian: mRNA Vaccine Pipeline Status
- 16.14.4 Strategic Outlook
- 16.15 Ethris
- 16.15.1 Company Snapshot
- 16.15.2 Company Overview
- 16.15.3 Ethris: mRNA Vaccine Pipeline Status
- 16.15.4 Strategic Outlook
17 Conclusion and Recommendations
- 17.1 Concluding Remarks from
- 17.2 Recommendations for Market Players